In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Achieve Life Sciences (ACHV – Research Report), with a price target of $20.00. The company’s shares opened today at $6.21.
According to TipRanks, McCarthy is an analyst with an average return of -27.8% and a 22.33% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Lineage Therap, and SELLAS Life Sciences Group.
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $23.50, which is a 278.42% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $35.00 price target.
See the top stocks recommended by analysts >>
ACHV market cap is currently $147M and has a P/E ratio of -1.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
- Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
- ACHV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
- Achieve Life Sciences announces Phase 2 ORCA-V1 trial results
